Evidence map›Paper›PMID 40506728›Full record

ArticleMalaria journal2025

Plasmodium falciparum multidrug resistance 1 gene polymorphisms associated with outcomes after anti-malarial treatment.

Veronika R Laird, Mateusz M Plucinski, Meera Venkatesan, Kelsey A Rondini, Milijaona Randrianarivelojosia, Mauricette N Andriamananjara, Hawela Moonga, Deus S Ishengoma, Arlindo Chidimatembue, Pedro Rafael Dimbu and 13 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Malaria journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Emergence of chloroquine-sensitiveEmerging microbes & infections · 2025
    Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Veronika R LairdDepartment of Epidemiology, Emory University, Atlanta, GA, USA. veronika.laird97@gmail.com.
Mateusz M PlucinskiMalaria Branch, Division of Parasitic Diseases and Malaria, Centers for Disease Control and Prevention, US President's Malaria Initiative, Atlanta, GA, USA.
Meera VenkatesanUS President's Malaria Initiative, United States Agency for International Development, Washington, DC, USA.
Kelsey A RondiniDepartment of Epidemiology, Emory University, Atlanta, GA, USA.
Milijaona RandrianarivelojosiaInstitut Pasteur de Madagascar, Antananarivo, Madagascar.
Mauricette N AndriamananjaraDirection de La Démographie et des Statistiques Sociales, Institut National de La Statistique, Antananarivo, Madagascar.
Hawela MoongaNational Malaria Elimination Centre, Zambia Ministry of Health, Lusaka, Zambia.
Deus S IshengomaNational Institute for Medical Research, Dar es Salaam, Tanzania.
Arlindo ChidimatembueCentro de Investigação em Saúde de Manhiça (CISM), Maputo, Mozambique.
Pedro Rafael DimbuNational Malaria Control Program, Ministry of Health, Luanda, Angola.
Adicatou-Laï AdeothyNational Malaria Control Program, Ministry of Health, Porto-Novo, Benin.
Abdoul Habib BeavoguiCentre National de Formation et de Recherche en Santé Rurale de Maferinyah, Forecariah, Guinea.
Simon KariukiKenya Medical Research Institute (KEMRI)-Centre for Global Health Research, Kisumu, Kenya.
Sam L NsobyaInfectious Diseases Research Collaboration (IDRC), Kampala, Uganda.
Aline UwimanaMalaria and Other Parasitic Diseases Division, Rwanda Biomedical Centre (RBC), Kigali, Rwanda.
Gauthier Mesia KahunuUnit of Clinical Pharmacology and Pharmacovigilance University of Kinshasa, Kinshasa, Democratic Republic of the Congo.
Ashenafi AssefaEthiopian Public Health Institute, Arbegnoch Street, Addis Ababa, Ethiopia.
Ousmane A KoitaLaboratoire de Biologie Moléculaire Appliquée, Université des Sciences, des Techniques et des Technologies de Bamako, Bamako, Mali.
Naomi W LucchiU.S. President's Malaria Initiative, US Centers for Disease Control and Prevention, Kigali, Rwanda.
Samaly S Svigel SouzaLaboratory Science and Diagnostic Branch, Malaria Branch, U.S. Centers for Disease Control and Prevention, Atlanta, GA, USA.
Zhiyong ZhouLaboratory Science and Diagnostic Branch, Malaria Branch, U.S. Centers for Disease Control and Prevention, Atlanta, GA, USA.
Leah F MoriartyMalaria Branch, Division of Parasitic Diseases and Malaria, Centers for Disease Control and Prevention, US President's Malaria Initiative, Atlanta, GA, USA.
Eric S HalseyMalaria Branch, Division of Parasitic Diseases and Malaria, Centers for Disease Control and Prevention, US President's Malaria Initiative, Atlanta, GA, USA. ycw8@cdc.gov.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPlasmodium falciparum multidrug resistance transporter 1 (Pfmdr1) gene mutations are associated with altered response to artemisinin-based combination therapy (ACT), particularly the combinations containing the partner drugs lumefantrine and amodiaquine (i.e., artemether-lumefantrine [AL] and artesunate-amodiaquine [ASAQ]). Past studies of Pfmdr1 single nucleotide polymorphisms (SNPs) at codons 86, 184, and 1246 have shown different responses to AL and ASAQ.

methodsTo determine whether infection with parasites carrying specific Pfmdr1 SNPs leads to increased risk of recurrent parasitaemia (recrudescent or new infection), data from 3,915 samples from 16 therapeutic efficacy studies from 13 African countries between 2013 and 2019 were analysed.

resultsPatients treated with AL and infected with parasites carrying Pfmdr1 N86 were at greater risk of recurrent infection than those whose parasites carried 86Y. After treatment with ASAQ, individuals infected with parasites that carried Pfmdr1 86Y were more likely to experience a recurrent infection.

conclusionsThese results support prior studies that suggested: (1) patients given AL and infected with parasites carrying N86 were more likely to experience a recurrent infection; (2) patients given ASAQ and infected with parasites carrying 86Y were more likely to experience a recurrent infection. These findings suggest that ACT and Pfmdr1 genotype may influence outcome after Plasmodium falciparum infection.

Indexed as

AmodiaquineAntimalarialsATP-Binding Cassette, Sub-Family C ProteinsMalaria, FalciparumPlasmodium falciparumPolymorphism, Single NucleotideAfricaArtemether, Lumefantrine Drug CombinationArtemisininsDrug CombinationsHumansTreatment OutcomeAmodiaquineamodiaquine, artesunate drug combinationAntimalarialsArtemether, Lumefantrine Drug CombinationArtemisininsATP-Binding Cassette, Sub-Family C ProteinsDrug CombinationsMdr1 protein, Plasmodium falciparumAfricaAntimalarialsDrug resistanceMalariaPlasmodium falciparum

Identifiers

PMID40506728
PMCPMC12160118

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.